NEW YORK (GenomeWeb) – Exact Sciences reported late on Sunday that its preliminary fourth quarter revenues rose 64 percent year over year thanks to 66 percent growth in the number of completed Cologuard colorectal cancer diagnostic tests during the quarter.

For the three months ended Dec. 31, 2018, the company expects to report revenues of $142.5 million to $143.5 million, and said it completed approximately 292,000 Cologuard tests. Analysts are expecting revenues of $127.0 million for the quarter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.